PSDalpha
PSDalpha is a photoactivatable PS-Degron targeting estrogen receptor α (ERα/ESR1), with a Ki of 72.8 nM for ERα. PSDalpha consists of an ERα-targeting estradiol moiety conjugated via an alkyne bond to triphenylamine-benzothiadiazole (TB), an aggregation-induced emission (AIE) photosensitizer. Upon visible light irradiation, PSDalpha generates singlet oxygen (1O2) and induces controllable ERα degradation. PSDalpha also induces G1 phase arrest and apoptosis. PSDalpha can be used in studies related to ERα-positive breast cancer and light-controlled targeted protein degradation.
For research use only. We do not sell to patients.
- CAS No.: 2906869-08-5
- Formula: C44H39N3O2S
- Molecular Weight:673.86
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ERα 72.8 nM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | EC50 |
17 nM
|
ERα degradation in human MCF-7 breast cancer cells incubated for 6 h, irradiated for 30 min, harvested 4 h post-irradiation, measured via immunoblotting.
ERα degradation in human MCF-7 breast cancer cells incubated for 6 h, irradiated for 30 min, harvested 4 h post-irradiation, measured via immunoblotting.
|
35164509 |
| MCF7 | EC50 |
0.5 nM
|
ERα degradation in human MCF-7 breast cancer cells incubated for 6 h, irradiated for 45 min, harvested 4 h post-irradiation, measured via immunoblotting.
ERα degradation in human MCF-7 breast cancer cells incubated for 6 h, irradiated for 45 min, harvested 4 h post-irradiation, measured via immunoblotting.
|
35164509 |
| MCF7 | IC50 |
8.9 μM
|
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 15 min, viability measured 72 h post-irradiation by MTT assay.
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 15 min, viability measured 72 h post-irradiation by MTT assay.
|
35164509 |
| MCF7 | IC50 |
6.1 μM
|
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 30 min, viability measured 72 h post-irradiation by MTT assay.
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 30 min, viability measured 72 h post-irradiation by MTT assay.
|
35164509 |
| MCF7 | IC50 |
5.9 μM
|
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 45 min, viability measured 72 h post-irradiation by MTT assay.
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, single irradiated for 45 min, viability measured 72 h post-irradiation by MTT assay.
|
35164509 |
| MCF7 | IC50 |
0.024 μM
|
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, daily irradiated for 45 min over 3 days, viability measured 72 h post-initial incubation by MTT assay.
Cell viability inhibition in human MCF-7 breast cancer cells incubated for 6 h, daily irradiated for 45 min over 3 days, viability measured 72 h post-initial incubation by MTT assay.
|
35164509 |
In Vitro
PSDalpha (1 μM; 15 mW/cm2) generates singlet oxygen under illumination, with a singlet oxygen quantum yield of 0.12, whereas no corresponding singlet oxygen ESR signal is detected under dark conditions[1].
PSDalpha binds to the ligand-binding domain of human ERα with a Ki of 72.8 nM; isothermal titration calorimetry (ITC) shows that PSDalpha interacts with ERα in an exothermic manner, with a binding molar ratio of approximately 1:1[1].
PSDalpha (1 μM) reduces the level of purified ERα after 15 min of illumination, and ERα disappears completely when illumination is extended to 30-45 min; PSDalpha remains inert under dark conditions[1].
PSDalpha (0.1 or 1 μM; 6 h; 460 nm light for 30 min) induces time-dependent ERα degradation in MCF-7 cells, with obvious degradation detectable within 2 h after illumination; 0.1 μM PSDalpha leads to complete ERα degradation at 8 h after illumination, followed by gradual recovery of ERα[1].
The ERα degradation induced by PSDalpha in MCF-7 cells is light-duration dependent, with EC50 values of 17 nM and 0.5 nM upon 460 nm light irradiation for 30 min and 45 min, respectively[1].
PSDalpha inhibits the viability of MCF-7 cells after a single irradiation, with IC50 values of 8.9, 6.1, and 5.9 μM following 15, 30, and 45 min of irradiation, respectively; PSDalpha shows essentially no obvious toxicity to MCF-7 cells under dark conditions[1].
Optogenetic degradation of ERα by PSDalpha arrests MCF-7 cells at the G1 phase, while the proportions of cells in the S and G2/M phases decrease with increasing illumination time; the G1/S arrest induced by a single illumination is relieved after approximately 24 h as ERα is restored, whereas repeated illumination can block the G1/S transition again[1].
PSDalpha increases the proportion of late apoptotic cells in MCF-7 cells, and repeated irradiation induces a more pronounced apoptotic response than single irradiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7
-
Concentration:0.1 or 1 μM
-
Incubation Time:6 h; 30 min irradiation; 2-24 h post-irradiation
-
Result:Induced time-dependent ERα degradation; complete depletion occurred at 8 h with 0.1 μM.
-
Cell Line:MCF-7
-
Concentration:0.1 nM-10 μM
-
Incubation Time:6 h; 30 or 45 min irradiation; 4 h post-irradiation
-
Result:Induced ERα degradation with EC50 values of 17 nM and 0.5 nM after 30- and 45-min irradiation, respectively.
-
Cell Line:MCF-7
-
Concentration:0.01 μM
-
Incubation Time:6 h; 0-45 min irradiation
-
Result:Increased cytochrome c release as irradiation time increased.
-
Cell Line:MCF-7
-
Concentration:0.01, 0.1, 1 μM
-
Incubation Time:30 min irradiation; assessed at 3 d
-
Result:Increased late apoptosis, with a stronger response under daily irradiation.
Chemical Information
-
CAS No. 2906869-08-5
-
Molecular Weight 673.86
-
Formula C44H39N3O2S
-
SMILES
C[C@@]12[C@](CC[C@]2(O)C#CC3=CC=C(C4=CC=C(C=C4)N(C5=CC=CC=C5)C6=CC=CC=C6)C7=NSN=C37)([H])[C@@]8([H])[C@@](CC1)([H])C9=CC=C(O)C=C9CC8
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)